THR 184

Drug Profile

THR 184

Alternative Names: AA-184; THR-184

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Thrasos Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Apoptosis regulatory proteins; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Bone morphogenetic protein receptor type I agonists; Bone morphogenetic protein receptor type II agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute kidney injury

Most Recent Events

  • 12 Jun 2017 Discontinued - Phase-II for Acute kidney injury (Prevention) in USA and Canada (IV)
  • 29 Feb 2016 Efficacy and adverse events data from a phase II trial in Acute kidney injury released by Thrasos
  • 29 Feb 2016 Thrasos completes a phase II trial in Acute kidney injury (Prevention) in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top